About Us
Evolve is a new kind of biologics company founded for a clear purpose: bringing critical plasma proteins to the people who need them.
Evolve is a new kind of biologics company. We’re built around a next-generation technology for bringing critical therapeutics to the people who need them.
People with many rare diseases rely on therapies made from proteins extracted from blood plasma. For the past 80 years, these proteins have been captured through a largely unchanged yet expensive process. Until now.
We believe our patented next-generation technology, PlasmaCap EBA®, is the first major advancement in the field since the 1940s. We believe it will help us deliver critical plasma-derived therapeutics at higher levels of purity, efficiency, and quality than conventional methods can.
Ultimately, Evolve aims to improve the lives of people within a largely underserved market—building a broad and innovative product portfolio in the process.
Vision
We believe we can deliver plasma-derived therapeutics at higher levels of purity, efficiency, and reliability than anyone in our industry currently delivers.
As a first step toward achieving that vision, we have advanced the technology used to extract plasma proteins from blood. We believe our patented technique, PlasmaCap EBA®, is the first major innovation in this area in the past 80 years.
We believe this technique will allow us to advance the quality of plasma-derived therapeutics. It has the potential to extract more value from each liter of precious donor plasma as compared to legacy technology.
And this efficiency drives reliability—in both quality and consistency of supply. Because our technology is proprietary and protected, and we have direct control of our manufacturing, we expect our supply to be more consistent and predictable than today’s options.
We think it’s about time someone advanced the way biologics are delivered. So Evolve is doing just that.
Milestones
Evolve may be a new company, but the essence of our story stretches back decades—and it will continue to be written for years to come.
Leadership
We’re led by a proven executive team.
Our experienced and passionate leaders have spent decades honing their expertise across leading pharmaceutical and biologics organizations.
Jim Caggiano
Chief Executive Officer
Jim Caggiano
Chief Executive Officer
Jim is a seasoned and dynamic leader bringing over 30 years of biotech, pharmaceutical and medical device experience focused on improving the lives of patients across a number of therapeutic areas.
He has worked in senior leadership roles for successful companies including TAP Pharmaceuticals, Allergan, Abbott Laboratories, Valeant and Dendreon, with a proven track record of creating value in turnaround situations and managing business transitions.
Jim received a B.S. in agricultural economics (business) from Cornell University and an M.B.A. from the Kellogg School of Management at Northwestern University. Prior to entering industry, he served as an officer in the Armor Branch of the United States Army.
Chris Carr
Chief Financial Officer
Chris Carr
Chief Financial Officer
Chris has held several senior leadership roles during a period of over 30 years in the Biotech industry and joined Evolve following his most recent role as Chief Financial Officer for AEON Biopharma. Prior to AEON, Chris served on the Board of Directors and as Chief Financial Officer and Executive Vice President of Finance and Information Technology of Dendreon Pharmaceuticals LLC. Prior to Dendreon, Chris was at Abbott Laboratories, Inc., where he served in several senior financial and business development roles, latterly as Controller and Senior Director of Greater China Nutrition, Chris previously held escalating senior finance roles with PerkinElmer, Inc. and Genzyme Corporation and received a B.S. in Finance and Economics from Boston College.
David Holliday
Chief Commercial Officer
David Holliday
Chief Commercial Officer
With over 30 years of pharmaceutical and biologics experience, David has held progressively senior commercial roles in both private and public companies.
He has successfully launched and commercialized a number of key >$1B biologics in the United Kingdom, United States, and other global markets, most recently, as VP Commercial Operations for Octapharma US. Prior to Octapharma US, he was Global Vice President of Marketing Operations and Hemophilia for Baxter (now Takeda) and also led their Bioscience business in the UK, following a 17-year career with Novartis. David holds a DMS from Kingston University in London.
Mark Krause
Senior VP, Operations
Mark Krause
Senior VP, Operations
Mark served as Head of Plasma Proteins at Therapure Biopharma Inc. from 2011 until the formation of Evolve Biologics.
He previously held progressively senior positions within the finance operations at Valeant (formerly Biovail). As Director, Financial Analysis and Planning, Mark worked closely with business development, R&D, and manufacturing, particularly during licensing transactions. Mark earned both a BSc in biology from the University of British Columbia and an MBA from Richard Ivey School of Business, and is a Certified Professional Accountant.